Hozefa S. Bandukwala
Southborough,MA
Summary
A visionary and results-driven Strategic R&D Leader and Venture Builder with a distinguished career spanning over 15 years. Possessing a unique ability to translate highly complex, foundational biological concepts into commercially viable, high-value biopharmaceutical enterprises. This is underpinned by fusion of C-level executive leadership experience—driving corporate strategy and execution—and deep technical expertise in immunology, inflammation, and therapeutic development. Proven track record in architecting proprietary technology platforms from concept to market readiness, which has successfully secured over $150M in both non-dilutive partnerships and venture capital financing. Expert in employing a "future-backwards" strategy, identifying emerging scientific whitespace and leveraging an innate innovative and entrepreneurial mindset—evidenced by the filing and granting of numerous high-impact patents—to systematically de-risk cutting-edge science. A master at recruiting, mentoring, and leading high-performing, multi-disciplinary teams across research, preclinical development, and business functions to achieve ambitious corporate milestones.
Overview
26
26
years of professional experience
Work History
Vice President & Science Partner
FLAGSHIP PIONEERING
01.2022 - Current
- Lead ideation and NewCo creation, shaping foundational scientific concepts into therapeutic paradigms.
- Prologue Medicines (Founding CSO): Co-founded the pioneer in viral-proteome therapeutics.
- Strategic Architecture: Designed the DELVE platform to decode viral evolution for human therapeutic use, resulting in two differentiated development candidates for immune diseases.
- Innovation: Authored foundational patents for viral-derived immunomodulatory proteins (US20240269263A1).
- Apriori Bio (Interim CSO): Provided scientific leadership through critical early-stage development cycles.
- Strategic Oversight: Directly responsible for future-backwards strategy and pipeline architecture, positioning assets for maximum strategic optionality and value inflection.
Vice President, Immune-Mediated and Metabolic Diseases
SIGILON THERAPEUTICS
01.2019 - 01.2021
- Member of the Senior Leadership Team (SLT) tasked with expanding the SLTx platform.
- Department Creation: Established a new department to enhance the Shielded Living Therapeutics platform, leading a cross-functional pipeline for immune-mediated diseases.
- Translational Leadership: Spearheaded development of continuous delivery systems for biologics (e.g., IL-10) to modulate immune function in preclinical models.
- IP Portfolio Growth: Filed five major patents regarding cell-based therapies and antigen-specific immune tolerance.
Senior Director, Head of Discovery Biology
RHEOS MEDICINES
01.2018 - 01.2019
- Executive leader at a Third Rock Ventures-backed company specializing in immunometabolism.
- Organizational Scaling: Built the entire biology organization and laboratory infrastructure from the ground up.
- Commercial Success: Delivered the datasets that secured a transformational partnership with Roche ($40M upfront).
- Discovery Strategy: Defined and executed target discovery strategy, managing both internal teams and external collaborations.
Consultant
THIRD ROCK VENTURES
01.2017 - 01.2018
- Developed the tactical and scientific blueprint for the immunometabolism platform.
- Capital Acquisition: Successfully presented the execution strategy to investors to obtain a $60M Series A.
Associate Research Fellow / Head of Immuno-Metabolism Lab
PFIZER INC.
01.2016 - 01.2017
- Led large-scale discovery and translational efforts in autoimmunity and inflammation.
- Innovation: Developed a Chemogenomics and RNAi screening platform to identify novel immunology targets.
- Portfolio Management: Led development of internal preclinical programs and identified external partnership opportunities.
Consultant
CALCIMEDICA
01.2011 - 01.2013
- Provided scientific input and feedback to the discovery/preclinical research team on the identification of novel therapeutic areas and the use of appropriate preclinical models to test the efficacy of small molecule inhibitors developed by CalciMedica for treatment of autoimmune diseases such as Psoriasis, Asthma, EAE and inflammatory bowel diseases.
- Provided critical analyses of data obtained from preclinical studies and aid in the identification of ideal biomarkers to predict the efficacy of their compounds.
Instructor
LA JOLLA INSTITUTE OF ALLERGY AND IMMUNOLOGY
01.2011 - 01.2013
- Productively collaborated with GlaxoSmithKline to investigate the effects of a small molecule inhibitor of Bromodomain and ExtraTerminal domain containing (BET) proteins in the pro-inflammatory functions of T cells. Demonstrated that inhibition of BET protein function results in a long-term suppression of the ability of autoreactive T cells to induce neuroinflammation in murine models of Multiple Sclerosis.
- Directed a team of two post-doctoral fellows and a research technician to evaluate the role of epigenetic regulator, Jarid2 in the regulation of NKT cell function.
- Supervised a team of a research technicians and a post-doctoral fellow to generate a mouse with conditional deletion of a protein that regulates NFAT function using TALENs.
- Advised post-doctoral fellow in a collaborative program to evaluate the role of Nr4a family members in neuroinflammation.
- Developed and optimized a novel method for deep-sequencing nascent RNAs in primary CD4+ T cells. This technology provides a very high-resolution picture of the transcriptional landscape of immune cells and is well suited to identify novel target genes and biomarkers.
- Optimized an immunocytochemistry based high-throughput method for analysis of nuclear translocation of transcription factors.
Instructor
CHILDREN’S HOSPITAL, HARVARD MEDICAL SCHOOL
01.2010 - 01.2011
- Developed a mouse bearing a ‘floxed’ allele for the conditional deletion of Tet2, a member of the Tet family of proteins, which reverse DNA-methylation and investigated the requirement of Tet2 in hematopoiesis.
- Demonstrated a suppressive role of Tet2 in myeloid cell differentiation
- Performed RNAi experiments to ‘knockdown’ expression of TET proteins in dendritic and monocytic cells and demonstrated an important role of TET1 in IL-1β production by human THP monocytic cells
- Evaluated the ability of Tet2-/- dendritic cells to express cell surface MHC class II, costimulatory molecules and prime naïve T cells
Post Doctoral Fellow
IMMUNE DISEASE INSTITUTE, HARVARD MEDICAL SCHOOL
01.2007 - 01.2010
- In collaboration with Dr. Lin Chen, we solved the crystal structure of transcription factor FOXP3 and identified a novel dimerization interface, which is critical for the induction of suppressor functions in regulatory T cells. These studies provided a structural and molecular mechanism to explain how certain naturally-occurring mutations in FOXP3, result in severe autoimmunity in affected individuals
- Performed site-directed mutagenesis to introduce specific mutations in the transcription factor FOXP3.
- Retrovirally transduced T cells and evaluated the effects of these mutations on the ability of FOXP3 to induce suppressors functions in T cells using mouse models of Type-1 diabetes and multiple sclerosis.
- Performed microarray analyses to identify novel targets of FOXP3.
- Identified a novel role of the retinoic acid transporter, Stra6 for suppressor functions of regulatory T cells and tested its requirement to ameliorate inflammation in a mouse model of colitis.
Graduate Research
UNIVERSITY OF CHICAGO
01.2000 - 01.2007
- Elucidated a novel pathway through which antibodies affect T cell inflammatory responses via ligation of Fcγ receptors on dendritic cells. These studies demonstrated that presence of antigen-specific IgG antibodies could also serve as a substantial risk factor for inflammatory airway diseases such as asthma and were featured in the Journal of Experimental Medicine. These studies have provided the foundation of two additional studies, which were published in the Journal of Clinical Investigation.
- Investigated the molecular mechanism by which FcγRIII signaling modulates dendritic cell activation by TLR ligands.
- Performed antigen uptake and processing assays with bone-marrow derived dendritic cells using a novel OVA-DQ conjugate which fluoresces upon lysosomal proteolysis
- Performed antigen-presentation assays to measure the ability of antigen-loaded dendritic cells to prime naïve CD4+ T cells.
- Determined the effects of deletion of Fc receptors on dendritic cells and their ability to direct CD4+ T- helper cell responses
- Intratracheally administered antigen-loaded dendritic cells to induce airway inflammation in a mouse model of asthma
Graduate Research
UNIVERSITY OF PITTSBURGH
01.2000 - 01.2001
- Pre-Doctoral Research
- Conducted research on the mechanisms by which human monocyte-derived dendritic cells uptake and process antigens in the laboratory of Dr. Russell Salter. Part of a research team that focused on the uptake of modified antibodies, which are found to predominate in the sera of autoimmune patients.
- Generated plasmacytoid (CD11c lo CD123 + ) and myeloid (CD11C + CD11b + ) dendritic cells from human peripheral blood mononuclear cells
- Investigated the identity of the receptors expressed on human dendritic cells which are required for binding and internalization of aglycosylated antibodies
- Performed flow-cytometry based antigen-uptake assays to measure rate of antigen uptake by different human dendritic cell subsets.
- Analyzed the spontaneous emergence of novel subsets in a hybrid B-cell/dendritic cell line isolated from a leukemia patient.
Education
Ph.D. - Immunology
University of Chicago
Chicago, IL01.2007
M.S. - Biotechnology
Indian Institute of Technology
Mumbai, India01.2000
B.S. - Life Sciences/Biochemistry with Honors
St. Xavier’s College
Mumbai, India01.1998
Skills
- Executive Leadership: Venture Architecture, Series A Funding, Pharma Partnerships, SLT Governance
- Strategic Innovation: Future-Backwards Strategy, Platform De-risking, Pipeline Architecture, IP Strategy
- Technical Authority: Immunology Discovery, Viral Proteomics, Immunometabolism, Translational Medicine
- Organizational Scaling: High-Performing Team Building, Cross-functional Management, R&D Culture
Affiliations
- Editorial Board: Frontiers in Immunology
- Review Editor: Immunological Memory
AWARDS
Post-Doctoral Fellowship, GlaxoSmithKline fellowship for inflammation research, “The role of domain-swapping in gene regulation by FOXP3” ($135,300), 2010-2011, Post-Doctoral Fellowship, Lady Tata Memorial fellowship for leukemia research, “The contribution of NFAT, TRAF6 and miRNAs in immunity and inflammation” (£26,000), 2007-2008, Annual Retreat, Best Research Poster Award, Immune Disease Institute, Harvard Medical School, Boston, MA, 2010, Best Research Poster Award, Committee on Immunology, University of Chicago, Chicago, IL, 2007, Lucielle P. Markey graduate fellowship for biomedical research, “The role of costimulatory molecules Asthma” ($60,000), 2002-2004, Silver Medal awarded for academic excellence, Indian Institute of Technology, Mumbai, India, 2000
PUBLICATIONS
- C.J. Bashor, I.B. Hilton, H. Bandukwala, D.M. Smith, O. Veiseh. Engineering the Next Generation of Cell-Based Therapeutics. Nat. Rev. Drug Discov, 21(9):655-675, 2022
- G.P. Mognol, B. Oliveira-Vieira, N. Pinheiro-Rosa, B.C. Peixoto, M. Boroni, E. González-Avalos, C. Secca, H. Bandukwala, A.C. Faria, A.Rao, J.P.B. Viola. The Transcriptional Cofactor IRF2BP2 Plays a Key Role in T Cell Homeostasis and Treg Cell Expansion. BioRxiv, 454283. https://doi.org/10.1101/2021.07.29.454283, 2021.
- D. Israni, S. Li, T. Moriguchi, H. Li, J. Sewell, J. Li, J. Huang, W. Wong, A. Khalil, H.Bandukwala, D. Peritt. Tunable Delivery of Parathyroid Hormone with the Shielded Living Therapeutics Platform Provides a New Modality for Treatment of Hypoparathyroidism. Mol. Ther. 29(4):248-249, 2021.
- S. Brites Boss, T. Vo, J. Li, J. Huang, L. Jansen, D. Peritt, H. Bandukwala. Continuous Delivery of IL-10 Using the Shielded Living Therapeutics Platform Leads to Modulation of Immune Cell Function and Prevents Liver Damage in Preclinical Model of Immune-Mediated Hepatitis. Mol. Ther. 29(4):342-343, 2021.
- S. Hiemer, S. Jatav, J. Jussif, J. Alley, S. Lathwal, M. Piotrowski, J. Janiszewski, R. Kibbey, T.Alves, D. Dumlao, A. Jha and H. Bandukwala. Integrated Metabolomic and Transcriptomic Profiling Reveals Novel Activation-Induced Metabolic Networks in Human T cells. BioRxiv, 635789. https://doi.org/10.1101/635789, 2019.
- I. Shaked, R.N. Hanna, H. Shaked, G. Chodaczek, H.N. Nowyhed, G. Tweet, R. Tacke, A.B. Basat, Z. Mikulski, S. Togher, J.Miller, A. Blatchley, S. Salek-Ardakani, M. Darvas, M.U. Kaikkonen, G.D. Thomas, S. Lai-Wing-Sun, A. Rezk, A. Bar-Or, C.K. Glass, H. Bandukwala and C.C. Hedrick. Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation. Nat Immunol. 16(12):1228-34, 2015.
- R.M. Pereira, G.J. Martinez, I. Engel, F. Cruz-Guilloty, B.A. Barboza, A. Tsagaratou, C.W. Lio, L.J. Berg, Y. Lee, M. Kronenberg, H.S. Bandukwala
- And A. Rao
- . Jarid2 is induced by TCR signaling and controls iNKT cell maturation. Nat Commun. Aug 8; 5:4540. doi: 10.1038/ncomms5540, 2014.
- Williams JW, Tjota MY, Clay BS, Vander Lugt B, Bandukwala HS, Hrusch CL, Decker DC, Blaine KM, Fixsen BR, Singh H, Sciammas R, Sperling AI. Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation. Nat Commun. 2013; 4:2990. doi: 10.1038/ncomms3990.
- S. Trifari, M.E. Pipkin, H.S. Bandukwala, T. Äijö, G. Martinez, R.Chen and A. Rao. A microRNA-directed program of effector CD8+ T cell differentiation. PNAS. 111(5):2047, 2014.
- M. Ko, J. An, H.S. Bandukwala, L. Chavez, T. Äijö, W.A. Pastor, M.F. Segal, H. Li, K.P. Koh, H. Lähdesmäki, P.G. Hogan, L. Aravind, A. Rao. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature. 497(7447):122-6, 2013.
- H.S. Bandukwala, A. Rao. 'Nurr'ishing Treg cells: Nr4a transcription factors control Foxp3 expression. Nature Immunology.14(3):201-3, 2013.
- H.S. Bandukwala
- J. Gagnon, S. Togher, J.A. Greenbaum, E.D. Lamperti, N.J. Parr, A.M. Molesworth, N. Smithers, K. Lee, J. Witherington, D.F. Tough, R.K. Prinjha, B. Peters, A. Rao
- . Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. PNAS. 109(36):14532-7, 2012.
- M. Ko 1 , H.S. Bandukwala 1 , J. An, S.B. Koralov, E. Lamperti, E. Thompson, R. Hastie, A. Tsangaratu, K. Rajewsky and A. Rao. Tet2 negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. PNAS. 108(35):14566-71, 2011.
- H.S. Bandukwala, Y. Wu, Y. Chen, J.C. Stroud, A. Rao, & L. Chen. Structure of a domain-swapped FOXP3 dimer on DNA and its function in regulatory T cells. Immunity. 34(4):479-91, 2011.
- S. Sharma, G.M. Findlay, H.S. Bandukwala, S. Oberdoerffer, B. Baust, Z. Li, V. Schmidt, P.G. Hogan, D.B. Sacks and A. Rao. Dephosphorylation of the nuclear factor of activated T cells (NFAT) transcription factor is regulated by an RNA-protein scaffold complex. Nature. 468(7325):839-43, 2010.
- M.Tahiliani, K.P. Koh, Y. Shen, W. A. Pastor, H. S. Bandukwala, Y. Brudno, S. Agarwal, L.M. Iyer, D.R. Liu, L. Aravind, A. Rao. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by the MLL fusion partner, TET1. Science. 324(5929):930-5, 2009.
- H.S. Bandukwala, M.S. Sundrud, A. Rao. Orphans against autoimmunity. Immunity. 29(2):167-8, 2008.
- B.S. Clay, R.A. Shilling, H.S. Bandukwala, T.V. Moore, J.L. Cannon, A.A. Welcher, J.V. Weinstock, AI Sperling. Inducible costimulator expression regulates the magnitude of Th2-mediated airway inflammation by regulating the number of Th2 cells. PLoS One. 4;4(11), 2009.
- J. Tong, B.S. Clay, C.M. Ferreira, H.S. Bandukwala, T.V. Moore, K.M. Blaine, J.W. Williams, L.M. Hoffman, R.A. Shilling, J.V. Weinstock, A.I. Sperling. Fas Expression on T Cells is Sufficient to Prevent Prolonged Airway Inflammation in a Murine Model of Asthma. American Journal of Respiratory Cellular and Molecular Biology. 2009.
- R.A. Shilling, B.S. Clay, A.G. Tesciuba, E.L. Berry, T.V. Tu, T.V. Moore, H.S. Bandukwala, J Tong, JV Weinstock, RA Flavell, T Horan, SK Yoshinaga, AA Welcher, JL Cannon, AI Sperling. CD28 and ICOS play complementary non-overlapping roles in the development of Th2 immunity in vivo. Cellular Immunology. 259(2):177-84, 2009.
- A.G. Tesciuba, R.A. Shilling, M.D. Agarwal, H.S. Bandukwala, B.S. Clay, T.V. Moore, J.V. Weinstock, A.A. Welcher and A.I. Sperling. ICOS Costimulation Expands Th2 Immunity by Augmenting Migration of Lymphocytes to Draining Lymph Nodes. Journal of Immunology. 181:1019-1024, 2008.
- H.S. Bandukwala, B.S. Clay, J. Tong, J.L. Cannon, R.A. Shilling, J.S. Verbeek, J.V. Weinstock, J. Solway and A.I. Sperling Signaling through FcγRIII is required for optimal Th2 responses and Th2-mediated airway inflammation. Journal of Experimental Medicine. 204(8):1875-89, 2007.
- P.D. Mody, J.L. Cannon, H.S. Bandukwala, K.M. Blaine, A.B. Schilling, K. Swier, A.I. Sperling Signaling through CD43 regulates CD4 T cell trafficking. Blood. 110(8):2974-82, 2007
- R.A. Shilling, H.S. Bandukwala and A.I. Sperling. Regulation of T:B cell interactions by the Inducible Costimulator molecule. Clinical Immunology. 121(1):13-8, 2006.
- J. Tong, H.S. Bandukwala, B.S. Clay, R.A. Anders, R.A. Shilling, D.D.Balachandran, B. Chen, J. Weinstock, J. Solway, K. Hamann, A.I. Sperling. Fas-positive T cells regulate the resolution of airway inflammation in a murine model of asthma. Journal of Clinical Immunology. 203(5):1173-84, 2006.
- R.A. Shilling, J.M. Pinto, D.C. Decker, D.H. Schneider, H.S. Bandukwala, J. Schneider, B. Camoretti- Mercado, C. Ober, and A.I. Sperling. Cutting Edge: Polymorphisms in the ICOS Promoter Region are associated with Allergic Sensitization and Th2 Cytokine Production. Journal of Immunology. 175(4):2061-5, 2005.
ABSTRACTS AND PRESENTATIONS
- Selected Invited Presentations:
- “Anti-anabolic drugs and immunosuppression.” Therapeutic Tolerance: First-In-Human Data, Newcastle University, Newcastle upon Tyne, UK, 2017. Host: Dr. John Isaacs
- “Aiding and a'BET'ting inflammation: The role of Bromodomain and ExtraTerminal domain containing proteins in the regulation of T cell effector functions”. Stadtman Symposium, National Institutes of Health, Bethesda, Maryland, MA. 2012. Host: Dr. Ethan Shevach
- “Transcriptional Regulation of T-cell Mediated Inflammation”. Sybilla Symposium, Turku Center for Biotechnology, Turku University, Finland. 2012. Host: Dr. Ritta Laahesma
- “Targeting Novel Epigenetic Regulators for Treatment of Hematopoietic Tumors and Inflammation”. 2 nd Epigenetics in Drug Discovery Conference, Boston, MA. 2012.
- “Inhibition of BET proteins limits pathogenicity of auto-reactive T cells”. 10 th Cytokines and Inflammation Conference, San Diego, CA. 2012
- “Inhibition of domain-swapping reveals novels pathways by which FOXP3 induces suppressor function in T cells”. Tempero Pharmaceuticals, Boston, MA. 2010. Host: Dr. Mark Sundrud.
- “A critical role of domain-swapping in FOXP3”. La Jolla Institute of Allergy and Immunology, La Jolla, CA. 2009. Host: Dr. Mitchell Kronenberg
- “Structure of a domain-swapped FOXP3 dimer and its function in regulatory T cells”. Juvenile Diabetes Research Foundation, Boston, MA. 2009. Hosts: Drs. Diane Mathis and Christophe Benoist
- Abstracts Selected for Oral Presentation
- “Selective inhibition of CD4 + T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors”. (Short Talk) La Jolla Immunology Conference. La Jolla, CA. 2012.
- “Inhibition of BET proteins limits pathogenicity of auto-reactive T cells”. (Short Talk). 14 th International Conference on Lymphocyte Activation and Immune Regulation, Newport Beach, CA. 2012
- “A critical role of domain-swapping in FOXP3 for its induction of suppressive potential in T cells.” (Short Talk). Keystone Symposia on Regulatory T cells, Keystone, CO. 2009
- “Signaling via Fcγ receptors on dendritic cells modulates their cytokine production and ability to influence T cell responses in vivo”. Autumn Immunology Conference, Chicago, IL. 2006
- “Signaling via Fcγ receptors on dendritic cells modulates their cytokine production and ability to influence T cell responses in vivo”. Keystone Symposia on Dendritic Cells at the Center of Innate and Adaptive Immunity: Eradication of Pathogens and Cancer and Control of Immunopathology, Vancouver, British Columbia, 2005
- “Ligation of the ICOS ligand, B7RP-1, augments LPS induced dendritic cell maturation, but suppresses IL-12 production”. Autumn Immunology Conference, Chicago, IL. 2004
- “ICOS Ligand regulates differentiation of CD4 + T cells”. Autumn Immunology Conference, Chicago, IL. 2002
- Selected Poster Presentations
- S.E. Hiemer, D. Dumlao, S. Jelinsky, M. Piotrowski, J. Janiszewski, A. Jha, R. Kibbey and H.S. Bandukwala “Metabolic profiling of human CD4+ T-cells using an integrated metabolomic-transcriptomic approach.” Keystone Symposium on Integrating Metabolism and Immunity, Dublin, Ireland. 2017.
- H.S. Bandukwala, J. Gagnon, J. Greenbaum, E. Lamperti, D. F. Tough, N. Parr, A. Molesworth, N. Smithers,J. Witherington, R. K. Prinjha, K. Lee, B. Peters and A. Rao. “An inhibitor of bromodomain binding to acetylated histones differentially modulates cytokine production from CD4+ T cells and limits the pathogenicity of autoreactive T cells”. Keystone Symposium on Regulation of Lymphocyte Signaling, Keystone, CO. 2012
- H.S. Bandukwala, B.S. Clay, J.L. Cannon, R.A. Shilling, J.L. Weinstock, S.J. Verbeek and A.I. Sperling, “Signaling through FcγRIII on dendritic cells is required for optimal Th2 responses and Th2-mediated airway inflammation” (Poster Presentation). Keystone Symposia on Allergy, Allergic Inflammation and Asthma, Breckenridge, CO, 2006
PATENTS
- IMMUNORECEPTOR INHIBITORY PROTEINS AND RELATED METHODS WO US US20250375499A1 Hozefa Saifuddin BANDUKWALA Flagship Pioneering Innovations Vii, Llc Priority 2024-01-26
- Filed 2025-01-24
- Published 2025-12-11
- METHODS OF MAKING STEM CELL-DERIVED ISLET-LIKE CELLS, AS WELL AS POPULATIONS AND COMPOSITIONS INCLUDING THE SAME WO TW WO2025117331A1 Hozefa BANDUKWALA Eli Lilly And Company Priority 2023-12-01
- Filed 2024-11-21
- Published 2025-06-05
- ENGINEERED PLASMIDIA AND RELATED METHODS WO US TW WO2025006419A1 Hozefa Saifuddin BANDUKWALA Flagship Pioneering Innovations Vii, Llc Priority 2023-06-26
- Filed 2024-06-25
- Published 2025-01-02
- IMMUNOMODULATORY COMPOSITIONS AND RELATED METHODS WO US US20240269263A1 Hozefa Saifuddin BANDUKWALA Flagship Pioneering Innovations Vii, Llc Priority 2023-02-06
- Filed 2024-02-06
- Published 2024-08-15
- IMMUNOMODULATORY PROTEINS AND RELATED METHODS WO US TW WO2024030856A3 Hozefa Saifuddin BANDUKWALA Flagship Pioneering Innovations Vii, Llc Priority 2022-08-01
- Filed 2023-07-31
- Published 2024-03-07
- COMPOSITIONS FOR CELL-BASED THERAPIES AND RELATED METHODS WO EP CN KR AU CA IL EP42422650A1 Hozefa BANDUKWALA Sigilon Therapeutics, Inc. Priority 2021-10-29
- Filed 2022-10-28
- Published 2024-09-04
- COMPOSITIONS, DEVICES AND METHODS FOR TREATING IMMUNE-MEDIATED INFLAMMATORY DISEASES WO EP US CN JP CA US20240307455A1 Hozefa Bandukwala Sigilon Therapeutics, Inc. Priority 2021-01-26
- Filed 2022-01-26
- Published 2024-09-19
- COMPOSITIONS, DEVICES AND METHODS FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE WO EP CN JP CA EP4284298A2 Hozefa BANDUKWALA Sigilon Therapeutics, Inc. Priority 2021-01-26
- Published 2023-12-06
- COMPOSITIONS, DEVICES AND METHODS FOR INDUCING IMMUNE RESPONSES TO INFECTIOUS AGENTS WO US US20230233679A1 Hozefa Bandukwala Sigilon Therapeutics, Inc. Priority 2020-05-04
- Filed 2021-05-04
- Published 2023-07-27
- BIOCOMPATIBLE DEVICES FOR CELL-BASED THERAPIES AND RELATED METHODS WO EP WO2022164933A3 Hozefa BANDUKWALA Sigilon Therapeutics, Inc. Priority 2021-01-26
- Published 2022-10-13
Invited Book Chapters
Mody PD and Bandukwala HS. The Molecular Basis of Allergy and Asthma. In Principles and Practice of Tropical Allergy and Asthma. W. Sheik, editor. Vikas Medical Publishing, Mumbai, 2006. ISBN No: 8188240001.
Timeline
Vice President & Science Partner
FLAGSHIP PIONEERING
01.2022 - Current
Vice President, Immune-Mediated and Metabolic Diseases
SIGILON THERAPEUTICS
01.2019 - 01.2021
Senior Director, Head of Discovery Biology
RHEOS MEDICINES
01.2018 - 01.2019
Consultant
THIRD ROCK VENTURES
01.2017 - 01.2018
Associate Research Fellow / Head of Immuno-Metabolism Lab
PFIZER INC.
01.2016 - 01.2017
Consultant
CALCIMEDICA
01.2011 - 01.2013
Instructor
LA JOLLA INSTITUTE OF ALLERGY AND IMMUNOLOGY
01.2011 - 01.2013
Instructor
CHILDREN’S HOSPITAL, HARVARD MEDICAL SCHOOL
01.2010 - 01.2011
Post Doctoral Fellow
IMMUNE DISEASE INSTITUTE, HARVARD MEDICAL SCHOOL
01.2007 - 01.2010
Graduate Research
UNIVERSITY OF CHICAGO
01.2000 - 01.2007
Graduate Research
UNIVERSITY OF PITTSBURGH
01.2000 - 01.2001
M.S. - Biotechnology
Indian Institute of Technology
B.S. - Life Sciences/Biochemistry with Honors
St. Xavier’s College
Ph.D. - Immunology
University of Chicago